NCT05393466View on ClinicalTrials.gov

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2026

Primary Completion Date

January 30, 2028

Study Completion Date

May 31, 2029

Conditions
Non-small Cell Lung Carcinoma
Interventions
DRUG

BPI-361175

BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.

All Listed Sponsors
lead

Xcovery Holdings, Inc.

INDUSTRY